Reporting owner · CIK 0001635393

Daly Richard J

SEC Form 4 history for the last 180 days across 1 company, 3 transactions and 2 filings.

DIRAquestive Therapeutics, Inc.
Open-market transaction mix100% buys2 buys · 0 sales

Period: Last 180 days

Trade dates in this period: Nov 6, 2026 – Nov 10, 2026

Transaction history, summary figures and purchase returns cover the last 180 days. Earlier activity is excluded from those sections.

Filings2Form 4 records
Buying$99.3k2 purchases
Selling$00 sales
Net value+$99.3kBuys minus sells · disclosed values

Latest insider transactions

Form 4 filings from the last 180 days.
Daly Richard J transactions · 20 per page
CompanyActivityDisclosed valueFiled (ET)
AQSTAquestive Therapeutics, Inc.
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$95.1kView disclosure →
AQSTAquestive Therapeutics, Inc.
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$4.24kView disclosure →
AQSTAquestive Therapeutics, Inc.
Director
DIR
Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Derivative securitySEC filing ↗
$0View disclosure →

Latest Form 4 facts

Quick context from source filings

Latest open-market transaction

The insider reported a buy at Aquestive Therapeutics, Inc. on Nov 10, 2026 valued at $95,094.63.

Review SEC filing
Latest sale

No open-market insider sale is available.

Monthly open-market activity

Last 1 reported month · purchases and sales

View exact monthly values
Monthly open-market source values
MonthPurchasesSalesBuy valueSale valueNet value
Nov 202620$99,330.63$0+$99,330.63

Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.

Ownership and transaction size

Ownership and ticket size

Average P/S size$49.7k
Median P/S size$49.7k
Direct3
Indirect0
Nov 10, 2026buy

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

No purchases currently have the price observations needed for a 90-day return. This may reflect incomplete price coverage or purchases that have not reached the return window.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

2 observations · Nov 10, 2026 – Nov 10, 2026. Window ends at the latest available report, not today.

Selected observation · Nov 10, 202628,025 shares reported
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
Nov 10, 20261,200Nov 12, 2026View transaction
Nov 10, 202628,025Nov 12, 2026View transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

Daly Richard J Insider Activity FAQ

SEC Form 4 context

Who is Daly Richard J?

Daly Richard J is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001635393.

Which companies has Daly Richard J reported transactions for?

Aquestive Therapeutics, Inc., CATALYST PHARMACEUTICALS, INC.

When was Daly Richard J's latest insider buy?

The insider reported a buy at Aquestive Therapeutics, Inc. on Nov 10, 2026 valued at $95,094.63.

When was Daly Richard J's latest insider sale?

No open-market insider sale is recorded in the last 180 days. Earlier filings are outside the visible history.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.